Drug Approval | January 10, 2023
The new project further expands the partner's long-term collaboration on new technologies for R&D
Zydus is the first company to receive final approval and launch Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg in the United States.
Fesoterodine Fumarate Extended-Release Tablets, 4 mg and 8 mg, have an estimated market size of US$ 177 million for twelve months ending Sep 2022
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
Subscribe To Our Newsletter & Stay Updated
